Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 28 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
33 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Boehringer Ingelheim Animal Health Belgium SA from Elsene, company number BE0445411231, closed financial year 2025 with a result of € 233,984 after tax. For that financial year Boehringer Ingelheim Animal Health Belgium SA recorded revenue of € 50.6 million and equity of € 4.2 million. Compared with financial year 2024, the result moved from € 1.4 million to € 233,984. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 4.2 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 233,984
▼ 83% vs 2024
Profit after tax over the fiscal year.
€ 233,984 paid out
100 % of the profit went to the shareholders, mostly to BOEHRINGER INGELHEIM AH INTERNATIONAL GMBH (100 % of the shares). That is where the money ends up.
People and assets in 2025
38.4
▼ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 5.7 million
▲ 4% vs 2024
€ 148,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 523
▼ 80% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3.9 million
Loans from banks and other lenders, long and short.
€ 13.3 million
▼ 4% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 111 days on average.
€ 1.4 million
▼ 7% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 36,176,964 | € 41,020,883 | € 46,854,124 | € 50,582,196 | ▲ 8% |
| Profit after taxes | € 1,003,522 | € 787,896 | € 1,372,451 | € 233,984 | ▼ 83% |
| Equity | € 4,246,253 | € 4,246,253 | € 4,246,253 | € 4,246,253 | |
| Total debts | € 12,234,107 | € 12,870,554 | € 16,635,781 | € 18,803,719 | ▲ 13% |
| Retained profit | € 756,070 | € 756,070 | € 756,070 | € 756,070 | |
| Dividend | € 2,003,522 | € 787,896 | € 1,372,451 | € 233,984 | ▼ 83% |
| Bank debt | € 0 | € 0 | € 0 | € 3,923,966 | |
| Balance sheet total | € 17,281,359 | € 18,116,025 | € 21,856,251 | € 24,038,190 | ▲ 10% |
| Employees (FTE) | 36.6 | 38.1 | 38.7 | 38.4 | ▼ 0.3 |
Key figures of Boehringer Ingelheim Animal Health Belgium SA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Boehringer Ingelheim Animal Health Belgium SA?
What happened at Boehringer Ingelheim Animal Health Belgium SA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Stephan KRICK stepped down as director. NBB
- Lukas HAUSCHILD stepped down as director. NBB
- Carla RAMON stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 233,984 (▼ 83% vs 2024). Source: NBB ↗
- Stephan KRICK became a director. NBB
- Christoph TAUTPHAEUS stepped down as director. NBB
- Lukas HAUSCHILD became a director. NBB
- Larisa NURKANOVIC stepped down as director. NBB
In short
From € 1 million profit in 2022 to € 233,984 profit in 2025.
Paid € 1.7 million in corporate taxes since 2022.
Best year ever: 2024, with € 1.4 million profit.
Paid out € 4.4 million in dividends to the owners in total.
A new publication or filing at Boehringer Ingelheim Animal Health Belgium SA? We notify you, reason included.
Follow Boehringer Ingelheim Animal Health Belgium SADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by BOEHRINGER INGELHEIM AH INTERNATIONAL GMBH (100%) and ANASCO GMBH (0%).
Directors
According to the 2025 annual accounts
Sebastian GUIJARRO
Director
Also active at: Boehringer Ingelheim SComm, BOEHRINGER INGELHEIM CENTRE SA
since 2024 · until 2025
Christoph TAUTPHAEUS
Director
since 2025 · until 2026
Carla RAMON
Director
Also active at: BOEHRINGER INGELHEIM CENTRE SA, Boehringer Ingelheim Veterinary Medicine Belgium NV
since 2025 · until 2029
Larisa NURKANOVIC
Director
since 2025 · until 2026
Luis Miguel VITORIA MAGRO CORREIA
Managing director
since 2023 · until 2025
Chiedza KAITANO
Director
since 2024 · until 2025
since 2026 · until 2029
Stephan KRICK
Managing director
since 2026 · until 2029
Shareholders
BOEHRINGER INGELHEIM AH INTERNATIONAL GMBH
100%
ANASCO GMBH
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Arnaud Fraiteurlaan 15/23
1050 Elsene
Noorwegenstraat 4
9940 Evergem
Active since 1 August 2020
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 33 companies are registered at this address.
All companies at this address →Laboratoires Titra
€ -7,222 gross margin · 2024
Boehringer Ingelheim SComm same network
€ 164.7 million revenue · 2025
BOEHRINGER INGELHEIM CENTRE SA same network
A.J.B. INTERIEUR
€ 26,086 gross margin · 2025
Krys Construct
€ 25,462 gross margin · 2024
+28 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0445.411.231
- VAT number
- BE 0445.411.231
- Registered office
- Arnaud Fraiteurlaan 15/23, 1050 Elsene
- Names & denominations
- Boehringer Ingelheim Animal Health Belgium SA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 8 October 1991
- Peppol
- Active · Active since 30 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten